Repligen (RGEN) Competitors $134.00 +4.18 (+3.22%) Closing price 04:00 PM EasternExtended Trading$134.01 +0.01 (+0.01%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN vs. TECH, A, DHR, TMO, BIIB, INCY, UTHR, NBIX, EXEL, and BMRNShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Thermo Fisher Scientific (TMO), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Repligen vs. Its Competitors Bio-Techne Agilent Technologies Danaher Thermo Fisher Scientific Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends. Does the media prefer TECH or RGEN? In the previous week, Repligen had 2 more articles in the media than Bio-Techne. MarketBeat recorded 10 mentions for Repligen and 8 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.00 beat Repligen's score of 0.80 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in TECH or RGEN? 99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 3.9% of Bio-Techne shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, TECH or RGEN? Bio-Techne has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Which has better earnings and valuation, TECH or RGEN? Bio-Techne has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Techne$1.16B7.36$168.10M$0.8266.35Repligen$634.44M11.87-$25.51M-$0.45-297.78 Is TECH or RGEN more profitable? Bio-Techne has a net margin of 10.89% compared to Repligen's net margin of -3.93%. Bio-Techne's return on equity of 13.17% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Bio-Techne10.89% 13.17% 10.17% Repligen -3.93%4.53%3.17% Do analysts recommend TECH or RGEN? Bio-Techne currently has a consensus price target of $71.36, indicating a potential upside of 31.16%. Repligen has a consensus price target of $170.75, indicating a potential upside of 27.43%. Given Bio-Techne's higher probable upside, equities analysts plainly believe Bio-Techne is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Techne 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50Repligen 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69 SummaryBio-Techne beats Repligen on 12 of the 16 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.29B$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E Ratio-297.788.0519.5820.23Price / Sales11.87296.11442.27127.79Price / Cash41.7942.7337.5058.41Price / Book3.817.748.085.60Net Income-$25.51M-$54.96M$3.16B$248.43M7 Day Performance5.21%6.04%3.77%5.15%1 Month Performance0.85%4.47%3.90%7.62%1 Year Performance10.79%6.12%34.22%21.56% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.7929 of 5 stars$134.00+3.2%$170.75+27.4%+7.4%$7.29B$634.44M-297.781,778Positive NewsAnalyst ForecastTECHBio-Techne4.9604 of 5 stars$51.45-0.8%$72.00+39.9%-26.2%$8.07B$1.16B62.743,100Positive NewsAnalyst ForecastAAgilent Technologies4.7098 of 5 stars$118.06-0.9%$140.92+19.4%-3.1%$33.54B$6.51B29.1518,100Analyst ForecastDHRDanaher4.8921 of 5 stars$197.40-0.7%$248.61+25.9%-16.2%$141.27B$23.82B38.3363,000Positive NewsAnalyst ForecastTMOThermo Fisher Scientific4.9577 of 5 stars$405.83-0.6%$604.05+48.8%-21.1%$153.20B$42.88B23.80125,000Positive NewsAnalyst ForecastBIIBBiogen4.9226 of 5 stars$125.59-0.4%$188.48+50.1%-41.9%$18.40B$9.68B12.407,605INCYIncyte4.5266 of 5 stars$68.10-0.4%$74.53+9.4%+13.2%$13.18B$4.24B212.822,617Insider TradeUTHRUnited Therapeutics4.9925 of 5 stars$287.35+1.1%$386.15+34.4%-6.8%$12.96B$2.88B11.471,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.7611 of 5 stars$125.69+0.2%$162.00+28.9%-6.8%$12.44B$2.36B42.611,800Trending NewsAnalyst ForecastInsider TradeEXELExelixis4.5865 of 5 stars$44.08+0.9%$43.56-1.2%+99.0%$12.02B$2.17B20.041,147Analyst ForecastOptions VolumeBMRNBioMarin Pharmaceutical4.8945 of 5 stars$54.97-0.4%$93.45+70.0%-28.1%$10.54B$2.85B20.443,040 Related Companies and Tools Related Companies Bio-Techne Alternatives Agilent Technologies Alternatives Danaher Alternatives Thermo Fisher Scientific Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGEN Stock Alerts